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Abstract
Background: Infections caused by vancomycin-resistant enterococci (VRE) are on the rise worldwide. Few studies
have tried to estimate the mortality burden as well as the financial burden of those infections and found that VRE
are associated with increased mortality and higher hospital costs. However, it is unclear whether these worse
outcomes are attributable to vancomycin resistance only or whether the enterococcal species (Enterococcus faecium
or Enterococcus faecalis) play an important role. We therefore aimed to determine the burden of enterococci
infections attributable to vancomycin resistance and pathogen species (E. faecium and E. faecalis) in cases of
bloodstream infection (BSI).
Methods: We conducted a retrospective cohort study on patients with BSI caused by Enterococcus faecium or
Enterococcus faecalis between 2008 and 2015 in three tertiary care hospitals. Data was collected on true hospital
costs (in €), length of stay (LOS), basic demographic parameters, and underlying diseases including the results of
the Charlson comorbidity index (CCI). We used univariate and multivariable regression analyses to compare risk
factors for in-hospital mortality and length of stay (i) between vancomycin-susceptible E. faecium- (VSEm) and
vancomycin-susceptible E. faecalis- (VSEf) cases and (ii) between vancomycin-susceptible E. faecium- (VSEm) and
vancomycin-resistant E. faecium-cases (VREm). We calculated total hospital costs for VSEm, VSEf and VREm.
Results: Overall, we identified 1160 consecutive cases of BSI caused by enterococci: 596 (51.4%) cases of E. faecium
BSI and 564 (48.6%) cases of E. faecalis BSI. 103 cases of E. faecium BSI (17.3%) and 1 case of E. faecalis BSI (0.2%)
were infected by vancomycin-resistant isolates. Multivariable analyses revealed (i) that in addition to different
underlying diseases E. faecium was an independent risk factor for in-hospital mortality and prolonged hospital stay
and (ii) that vancomycin-resistance did not further increase the risk for the described outcomes among E. faecium-
isolates. However, the overall hospital costs were significantly higher in VREm-BSI cases as compared to VSEm- and
VSEf-BSI cases (80,465€ vs. 51,365€ vs. 31,122€ p < 0.001).
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Conclusion: Our data indicates that in-hospital mortality and infection-attributed hospital stay in enterococci
BSI might rather be influenced by Enterococcus species and underlying diseases than by vancomycin resistance.
Therefore, future studies should consider adjusting for Enterococcus species in addition to vancomycin resistance in
order to provide a conservative estimate for the burden of VRE infections.
Keywords: Bloodstream infection, Vancomycin-resistant enterococci, Enterococcus faecium
Introduction
Enterococcus spp. are part of the normal gastrointestinal
flora. Among those pathogens, resistance to antimicrobial
substances, notably to vancomycin, results in limited thera-
peutic options [1, 2]. In recent years, hospital-acquired in-
fections (HAI) caused by vancomycin-resistant enterococci
(VRE) have emerged as a relevant burden on patients and
healthcare systems globally [3–5]. In order to reduce the
spread of resistant strains in hospitals, infection control
measures, e.g. contact precautions, have been proposed
[6, 7]. To assess the efficiency of VRE prevention
measures, the mortality- and financial burden of VRE
infections has to be assessed. However, the methodo-
logical approach on assessing VRE-burden remains
controversial [2, 8, 9] and only few studies have addressed
economic aspects [10–15]. As costs are often not available
as infection-attributable costs (costs after onset for
infection) length of stay (LOS) after onset of infection is
being used as a surrogate parameter [2, 8, 16].
Although analyses should compare VRE infections
to VSE-infected patients when the attributable effect
of vancomycin resistance is addressed, [2, 8, 16] prior
studies also utilized comparisons to cohorts with
non-enterococcus infections [17, 18] or cohorts
without infection [8, 12, 19–24]. Since the course of
enterococcal infections may also be influenced by the
enterococcus subspecies itself [2, 8, 9, 25, 26],
analyses not considering the pathogen species may
therefore be biased as result of the different virulence
of the pathogens.
In a large cohort of cases with bloodstream infection
(BSI), we therefore studied the influence of vancomycin
resistance and enterococcus subspecies on in-hospital
mortality, hospital costs and length of hospital stay.
Methods
Setting, study design and data collection
The study was conducted at three different tertiary care
hospitals of the Charité university hospital in Berlin,
with 3011-beds in total [27]. After a confirmatory ethics
vote was obtained from the Charité University Medicine
ethics committee (internal processing key EA4/229/17),
we performed a cohort study that included all cases of
BSI caused by Enterococcus faecalis or Enterococcus fae-
cium between January 1, 2008 and December 31, 2015.
Cases were identified in the Charité microbiology data-
base as hospitalized patients with blood cultures positive
for one of these pathogens. Data on costs and hospital
financial accounting was provided by the Charité
Department of Financial Controlling as true hospital
expenses in Euros. For all patients enrolled in this study,
the following demographic and clinical characteristics
were collected: age, sex, in-hospital death, length of
hospital stay (LOS), day of BSI onset and stay on an
intensive care unit (days). Length of stay in total and
after BSI onset were defined as length of stay until death
or discharge. The Charlson comorbidity index (CCI) was
obtained on the basis of the patients’ diagnosed comor-
bidities using the method of Charlson et al. and the
adaptation for the ICD-10 by Thygesen et al. [28, 29].
The original 17 Charlson comorbidity categories were
cumulated based on the affected organ system in the fol-
lowing ten disease categories: heart disease, cerebrovas-
cular disease, neurologic disease, lung disease, rheumatic
disease, gastrointestinal disease, liver disease, diabetes,
renal disease and cancer/immunological disease.
Definitions and statistical methods
Cases were defined as patients with BSI caused by
Enterococcus spp. (Enterococcus faecalis or Enterococcus
faecium) during the study period. Each patient was in-
cluded in the analysis once. Onset of BSI was defined as
the date of the first blood culture positive for the re-
spective pathogen. BSI was considered hospital-onset if
it occurred after the third day of hospitalization. Mortality
was assessed based on discharge alive or in-hospital death.
Data on hospital costs were derived from true hospital
costs (hospital expenses). The costs analyzed cover direct
costs to the hospital of treatment and diagnostics as well
as indirect hospital costs of activities without patient
contact (e.g. administration, hospital maintenance). The
estimated cost of individual cases was based on definite
performances and on settlement keys (e.g. nurse working
time per patient). Economic data was available on total
hospital costs and on daily costs. A differentiation of costs
before and after the infection was not available. However,
as length of stay directly correlates with hospital costs,
length of stay after onset for infection can be applied as
proxy for infection attributable additional expenditures
[2, 30, 31]. We therefore assessed the multiplicative
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effect on length of stay after BSI onset in a multivari-
able linear regression.
Descriptive, univariate analyses were performed for the
total cohort, stratified by enterococcus species (i.e.
vancomycin susceptible E. faecium vs. vancomycin sus-
ceptible E. faecalis) and by vancomycin susceptibility
(i.e. vancomycin susceptible enterococci vs. vancomycin
resistant enterococci). Since among E. faecalis-isolates
only one isolate was resistant against vancomycin, only
E. faecium (VSEm vs. VREm) were analyzed in the
second analysis. Additionally, we compared in univariate
analysis deceased patients and patients discharged alive.
The median and the interquartile range (IQR) were cal-
culated for continuous parameters; number and percent-
age were calculated for binary parameters. Univariate
differences were tested using the Wilcoxon rank-sum
test for continuous variables and the Chi-square test for
binary variables.
The two linear regression analyses were performed for
length of stay (LOS) after onset of enterococcal BSI by
stepwise forward variable selection. The continuous
parameters LOS after onset of BSI was log transformed
to achieve normal distribution. Only surviving patients
were included. Parameters considered in the full
model were vancomycin resistance OR pathogen
species (E. faecium or E. faecalis), sex, age and all
underlying diseases assessed as described above. From
the full model, parameters with the smallest
Chi-square statistic and p > 0.05 in the type III test
were removed. The regression coefficients were con-
verted to the measures of effect using an exponential
transformation and referred to as the multiplicative
effect (ME) of investigated parameters. P-values < 0.05
were considered significant.
Multivariable, binary logistic regression was performed
for in-hospital death by stepwise forward selection. The
p-values for including a variable in the model was 0.05
and for excluding 0.06 respectively. Odds ratios (HR)
with 95% confidence intervals (95% CI) were calculated.
Parameters considered in the model were sex, age,
pathogen species (E. faecium vs. E. faecalis) with the
interaction of the vancomycin resistance and all under-
lying diseases assessed as described above.
All analyses were performed using SPSS (IBM SPSS
statistics, Somer, NY, USA) and SAS (SAS Institute,
Cary, NC, USA).
Microbiological methods
If a blood stream infection was suspected, blood cultures
were drawn and incubated for up to seven days using
standard blood culture tubes (BACTEC, Becton
Dickinson Heidelberg Germany). If growth was detected,
gram staining and culturing were performed. MALDI
TOF MS and Vitek 2 automated system (Biomerieux
Marcy l’etoile France) were used for identification and
susceptibility testing of bacterial strains. They were
interpreted using EUCAST definitions.
Results
We initially extracted n = 24,086 clinical isolates diag-
nosed with Enterococcus faecium or Enterococcus faecalis
from the microbiology database. After excluding all
Fig. 1 Flowchart depicting patient recruitment based on blood culture isolates
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isolates not derived from blood cultures and correcting
for copy strains, 1242 patients with BSI caused by E. fae-
cium or E. faecalis were included in the analysis (Fig. 1).
Sufficient data on all relevant parameters was available
for 96.4% of the patients. Overall, this accounted for
1160 patients, 91% with infections caused by VSE and
9% by VRE. Table 1 gives an overview of the parameters
for all patients and shows the results of the (i) univariate
comparison of VSEm vs. VSEf and (ii) the comparison of
VSEm vs. VREm BSI cases. The highest in-hospital
mortality rate was found among VREm cases (50.5%)
followed by VSEm cases (39.6%) and VSEf cases (24.4%).
Also regarding LOS, highest numbers were found among
VREm cases (total LOS, 54 days) followed by VSEm
(42 days) and VSEf (32 days). In all three groups, the
Charlson comorbidity score was similar with a median
of 7.
In multivariable analyses on LOS after BSI onset
among vancomycin-susceptible enterococci cases, some
chronic diseases and E. faecium statistically significant
increased LOS as compared to E. faecalis (see Table 2).
Vancomycin-resistance was not found to additionally in-
crease LOS among E. faecium cases (see Table 2 and
Fig. 2). Regarding in-hospital death, patients with E.
faecium-BSI had a higher chance for death as compared
to E. faecalis-cases when only vancomycin-susceptible
cases were considered (see Table 3 and 4). Among E. fae-
cium cases, vancomycin-resistant was not found to be
an additional risk factor for death (Table 4).
Regarding economic aspects, almost all hospital costs
were significantly higher in the VREm BSI cohort
compared to the VSEm BSI and the VSEf cohort.
Discussion
During the last 15 years (since 2003), 4 meta-analyses
on mortality- and financial burden of VRE infections
[19, 22–24], and few recent studies on costs associ-
ated with VRE infections (not included in the
meta-analyses) were published [13, 15, 32]. The
studies demonstrate that vancomycin resistance is as-
sociated with overall worsened outcome (mortality,
length of stay and hospital costs). However, although
former studies indicated that E. faecium isolates
might be more virulent than E. faecalis isolates irre-
spective of vancomycin resistance [2, 8, 9, 26], many
of the above mentioned studies did not adjust for en-
terococcal subspecies. As Kaye et al. showed in 2004,
this could lead to an overestimation of the outcome
effects attributable to vancomycin resistance [9]. Some
of the authors discussed this issue in their articles, ar-
guing that meta-analyses cannot improve the quality
of data published [22, 24].
In our analyses, in-hospital mortality and length of
stay after BSI onset were independently associated with
underlying diseases, age and E. faecium but not with
vancomycin resistance.
Regarding mortality vancomycin resistance was
associated with increased in-hospital mortality in the
univariate analysis. This result is in agreement with
recent studies including three meta-analyses [19, 22, 24].
However, after adjusting for underlying diseases, age,
and species (E. faecium vs. E. faecalis), in-hospital
mortality was no longer associated with VRE. There are
several possible explanations for these differences with
other studies.
Systemic enterococci infections mainly occur in pa-
tients with severe underlying diseases and comorbidities
[33, 34] which also applies to our study cohort. Patients
had a very high Charlson comorbidity score with a
median of 7. In this regard, there was no significant
difference between the cases infected with E. faecalis, E.
faecium or vancomycin-resistant strains. Furthermore,
infections caused by antimicrobial-resistant bacteria are
often associated with increased morbidity and mortality
[19]. These differences are explained by the delay in or
even complete lack of an effective antibiotic treatment
despite the availability of effective drugs [1, 24].
Prematunge et al. adjusted for appropriate antimicrobial
Table 2 Multivariable linear regression on length of stay of surviving patients after BSI onset
Parameter VS-E. faecium vs. VS-E. faecalis VS-E. faecium vs. VR-E. faecium
ME Sig. CI 95 (lower-upper) ME Sig. CI 95 (lower-upper)
Renal Disease 1.588 0000 1.891 – 3.868 1516 0.001 1.472 – 4.201
Age (years) 0.659 0000 0.969 – 0.987 Not significant
Lung Disease 1.457 0000 1.800 – 4.342 1333 0.018 1.151 – 4.409
Gastrointestinal Disease 1.323 0001 1.959 – 11.025 Not significant
Liver Disease 1.270 0.003 1.256 – 3.100 1370 0.009 1.226 – 4.155
Vascular Disease 1.216 0.016 1.104 – 2.622 Not significant
Enterococcus species E. faecium 1.258 0.004 1.170 – 2.324 Not applicable
E. faecalis Reference = 1
BSI = bloodstream infection, CI95 = 95% confidence interval, ME multiplicative effect
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therapy but found that the differences remained [24].
Outcome differences resulting from varying pathogen-
icity of enterococci species is an alternative explanation
[35, 36]. In the multivariable analysis we found only
small differences for in-hospital mortality resulting
from vancomycin resistance, differences which are
insufficient to explain the univariate results. However,
we observed significantly increased mortality associated
with vancomycin-susceptible E. faecium compared to
vancomycin-susceptible E. faecalis.
Possibly because E. faecium is the most common type of
VRE worldwide and most E. faecalis isolates from
infections are vancomycin-susceptible, it might be a limi-
tation to most existing studies that this confounder is not
Fig. 2 Kaplan Meier survival curve of patients with enterococcal blood stream infection (BSI). VSE, vancomycin-resistant enterococcus. VRE,
vancomycin-susceptible enterococcus. Censored = left the hospital alive
Table 3 Univariate analysis on risk factors for in-hospital death
Parameter Discharge alive (n = 781) In-hospital death (n = 379) *P-value OR (CI 95)
Vancomycin resistance 6.7% (52) 13.7% (52) < 0.001 2.273 (1.512-3.417)
E. faecium 44.7% (349) 65.2% (247) < 0.001 2.311 (1.792-2.979)
E. faecalis 55.3% (432) 34.8% (132) 1 = Reference
Male 61.2% (478) 62.0% (235) 0.792 1.037 (0.805-1.334)
Age (years), median (IQR) 64.0 (51–73) 66.0 (56–74) 0.011 n.a.
Heart disease 25.1% (196) 35.4% (134) < 0.001 1.641 (1.258-2.14)
Vascular disease 19.6% (153) 27.7% (105) 0.002 1,57 (1,18-2.091)
Lung disease 19.6% (153) 26.1% (99) 0.011 1.461 (1.093-1.952)
Rheumatic disease 2.6% (20) 4.7% (18) 0.050 1.895 (0,99-3.626)
Gastrointestinal disease 4.1% (32) 5.8% (22) 0.195 1,44 (0,825-2.515)
Diabetes 26.8% (209) 27.4% (104) 0.807 1.033 (0,784-1.361)
Renal disease 46.9% (366) 78.1% (296) < 0.001 4.055 (3.061-5.371)
Liver disease 18.2% (142) 42.2% (160) < 0.001 3.283 (2.498-4.314)
Cancer/Immunological disease 41.4% (323) 45.4% (172) 0.194 1.176 (0,918-1.506)
Neurological disease 10.8% (84) 9.0% (34) 0.346 0,817 (0.537-1.241)
Categorical variables displayed as percentage and number; continuous variable displayed as median and interquartile range. *P-value, categorical variables tested
with Chi-square test, continuous variable tested with Wilcoxon rank sum test. BSI = blood stream infection, IQR = interquartile range, OR = odds ratio, CI95 = 95%
confidence interval. VRE = vancomycin-resistant enterococcus, VSE = vancomycin-susceptible enterococcus. N.a. = not applicable
Bold entries represent statistically significant factors
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considered [10–16, 18–24, 32]. Prematunge et al. already
pointed out in their 2016 meta-analysis, that it is possible
that many observations on VRE-associated outcome are
based on differences in the infection-causing species
rather than on vancomycin resistance [24].
Attempts to assess the pathogenicity of enterococci go
far back in time. In some of the previous studies, the
pathogenic potential of commensal E. faecium was
determined, whereas most of nowadays HAIs are caused
by isolates of a different E. faecium lineage [37, 38].
These so-called hospital-associated strain types (formerly
known as clonal complex CC17) differ from commensal
human and animal isolates by a distinct core and accessory
genome content. Ampicillin resistance is a phenotypic
marker of these hospital-associated strain types [39–41]. It
has been shown that AMP-R E. faecium isolates causing
healthcare-associated infections are in fact more pathogenic
than commensal variants [42, 43]. In a supplementary ana-
lysis (Additional file 1: Tables S1 and S2) we found that
95% of our E. faecium isolates were ampicillin-resistant
(AMP-R), in contrast to only 1% of the E. faecalis isolates.
Due to the uneven distribution of ampicillin resistance
over the two pathogens we were not able to assess
potential virulence differences between commensal and
hospital-associated isolates. However, our results are sup-
portive to previous population-based and molecular ana-
lyses of E. faecium from hospital-acquired infections.
Several reports have linked VRE infections with in-
creased costs [13, 15, 19, 32]. In the univariate analyses,
our data showed similar results as almost all costs were
significantly higher in VREm-BSI patients than in
patients with VSEm-BSI. Butler et al. reported that
pharmacy costs are the second most relevant driver of
increased costs, making up to 18% of the total amount
[21]. In our cohort, the percentage of pharmaceutical
costs for patients with VREm made up 21% of the total
hospital costs while they made up only 9% of the costs
of patents with BSI caused by VSEm (< 0,001). As we
were not able to attribute costs to particular agents,
these differences could be due to higher antibiotics costs
or to differences in underlying conditions treated. For
this reason, we analyzed the length of stay before and
after onset of BSI. Our data showed increased lengths of
stay overall and before onset of VREm-BSI, but not after.
Interestingly, all BSIs were classified as HAIs as none
occurred prior to day 3 after hospital admission. On
average, the BSI episodes occurred on day 16 of
hospitalization. Moreover, the same phenomenon was
observed in the analysis of the infection-attributable
LOS stratified by the two clinically relevant Entero-
coccus species. Cases with vancomycin susceptible E.
faecium BSI were in-hospital longer before onset of in-
fection than vancomycin susceptible E. faecalis cases. No
difference in LOS was observed after onset of infection.
This study has several limitations. The cases were identi-
fied retrospectively through a microbiological database and
6.6% lacked sufficient data for this analysis. We did not
have data on the course or severity of infection and the
antibiotic treatment performed. We did not have separate
data on true costs before and after the bloodstream infec-
tion. We did not perform molecular analyses on the entero-
cocci isolates to assess their potential virulence traits.
Conclusion
In our study, vancomycin resistance in patients with
Enterococcus faecium bloodstream infection was asso-
ciated with increased total costs, length of stay before
onset of infection, but not with infection-attributable
LOS or in-hospital mortality. We observed that
vancomycin-susceptible E. faecium infections were
more strongly associated with increased LOS and
mortality than vancomycin susceptible E. faecalis
infections and might indicate higher virulence of E.
faecium as compared to E. faecalis. In order to avoid
overestimation of VRE-attributable effects, in addition
to vancomycin-resistance species should be taken into
consideration in future studies assessing the burden
of VRE infections.
Table 4 Results of multivariable binary logistic regression of risk factors for in-hospital death after enterococcal bloodstream infection
Parameter VS-E. faecium vs. VS-E. faecalis VS-E. faecium vs. VR-E. faecium
OR P-value CI95 (lower-upper) OR P-value CI95 (lower-upper)
Age 1015 0,002 1005 – 1025 1016 0,010 1004 – 1029
Vascular disease 1407 0,042 1012 – 1956 Not significant
Renal disease 3120 0,000 2274 – 4280 4005 0,000 2708 – 5922
Liver disease 2909 0,000 2109 – 4011 2390 0,000 1618 – 3529
Enterococcus species VS-E. faecium 2023 0,000 1519 – 2695 Not applicable
VS-E. faecalis Reference = 1 Not applicable
Vancomycin-resistant Not applicable 1.283 0.300 0.801 – 2.057
Vancomycin-susceptible Not applicable Reference = 1
OR = odds ratio, CI95 = 95% confidence interval
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Additional file
Additional file 1: Table S1. Susceptibility towards Ampicillin among
cases. Table S2. Susceptibility towards Ampicillin among Isolate n=193
missing; AMP= Susceptibility to Ampicillin. R=Resistant. S=Susceptible.
RR= relative risk. CI95=95% confidence interval. (DOCX 34 kb)
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95% CI: 95% confidence interval; BSI: blood stream infection; CCI: Charlson
comorbidity index; HAI: hospital acquired infection; HR: Hazard ratios;
IQR: interquartile range; LOS: length of stay; ME: multiplicative effect;
VRE: vancomycin-resistant enterococcus; VREm: vancomycin resistant
Enterococcus faecium; VSE: vancomycin-susceptible enterococcus;
VSEf: vancomycin susceptible E. faecalis; VSEm: vancomycin susceptible
Enterococcus faecium
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